Clinical Research Details Clinical Research Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry (20192326) Study Description The CAMEO registry is a multicenter observational registry aimed at addressing optimal platelet inhibition during the early management of MI patients prior to coronary angiography or CABG. This registry will recruit approximately 10 sites over 3 years to collect information on 3,000 patients with NSTEMI or STEMI treated with cangrelor or an oral P2Y12 inhibitor into the registry. In this study, no clinical, instrumental, or laboratory assessments will be performed other than those required for disease management according to local best practice. Inclusion/Exclusion Criteria Inclusion: 1. The patient was hospitalized for STEMI and met one of the following inclusion criteria: o The patient received cangrelor at any time during his/her hospitalization for MI. o In the absence of cangrelor use, the patient received an oral P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) during his/her MI hospitalization AND either of the following: o The patient received an opiate/opioid within 24 hours prior to or during primary PCI for STEMI presentation. OR o The patient underwent coronary angiography followed by CABG during the index MI admission and received any P2Y12 inhibitor within 7 days prior to CABG. 2. The patient was hospitalized for NSTEMI and met one of the following inclusion criteria: o The patient received cangrelor during his/her hospitalization for MI. o In the absence of cangrelor use, the patient received an oral P2Y12 inhibitor during his/her MI hospitalization AND either of the following: o The patient underwent coronary angiography followed by CABG during the index MI admission and received any P2Y12 inhibitor within 7 days prior to CABG. OR o Any 2 of the following criteria without prior PCI or CABG: age> 60 years, male sex, diabetes, EF <40% prior hear failure Investigators Dominick J. Angiolillo, M.D., Ph.D., FACC Medicine